Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. - Wikidata - wikimedia - TriplyDB

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q27851456

about

KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Markers of resistance to anti-EGFR therapy in colorectal cancer Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Molecular origins of cancer: Molecular basis of colorectal cancer Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances Pharmacologic resistance in colorectal cancer: a review Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Somatic DNA mutation analysis in targeted therapy of solid tumours BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies New therapeutic strategies for BRAF mutant colorectal cancers Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer Lung cancer biomarkers, targeted therapies and clinical assays Treatment of colorectal cancer in the elderly Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention Precision medicine in colorectal cancer: the molecular profile alters treatment strategies New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?Recent applications of chemosensitivity tests for colorectal cancer treatment Molecular alterations and biomarkers in colorectal cancer Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine Colorectal Cancer Biomarkers: Where Are We Now?Multi-modality treatment of colorectal liver metastases Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Treatment of metastatic colorectal cancer: focus on panitumumab Mutation of the BRAF genes in non-small cell lung cancer How to select the optimal treatment for first line metastatic colorectal cancer Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer Signaling cross-talk in the resistance to HER family receptor targeted therapy CIViC database

P2860

e7300284a16d840c5ee19f367b9e3b557101df0a f8dd3de9c41ca6e3adc442dee34bbfb4ac19eea0

P248

Q21128654-F0D95847-EC57-450D-BA89-8A242AA48AB2 Q21142734-00DF8C3D-A60D-4A45-9E58-8C598FEC99A7 Q24243806-AFFDEB9A-2127-49AD-B921-E7CF5BE6557D Q24563539-BF03CCCD-47A3-4659-AC75-EDAB64147D25 Q24598640-9ED7724E-4A5E-4F55-9EDA-01F494B48056 Q24600031-160B55FF-33D3-44A0-9997-C1EECDBDF70B Q24617331-7647021E-7C3C-4E80-B349-B3590D483395 Q26738655-5821E6E3-6E41-4F14-9474-35FD970B4EA1 Q26748924-1F6BAB5E-E3D6-49EC-9928-C31FAD83D00B Q26751035-0BF1A0FE-298C-43CE-96C9-6B2F77EA6348 Q26751344-4CC82906-370E-4731-AA64-DBE8FF8EC770 Q26752752-38E820E1-D1CA-4586-BA6A-F9567F88E033 Q26766535-54BFEA98-0DAB-4826-A70E-D58D113E83DF Q26768427-D8720EE4-1E86-40DB-8EA0-1185AABA2FE0 Q26769850-08BD2372-842C-44E5-86B9-013C51D1AB15 Q26769958-F2189DAB-6E88-4A2A-BA63-3C3D2CABCA81 Q26770324-4DBC4CB0-0F75-4571-B5C4-EDFF29A47212 Q26772276-2860A910-21CA-480F-BAB8-598CBEF46DB8 Q26772277-7A343314-4236-4EF0-B61B-DDA8205AE68C Q26774605-052054D0-8EB0-4D61-99E9-85CED05C5911 Q26775396-77185439-BD93-4E7D-BE8A-6566CCD7428F Q26781457-6AAFFC78-1230-4B3A-8ED7-327477E09D3A Q26782809-C082EC53-900E-4912-B48F-2955E32B0024 Q26795558-F60CAEC9-C0D1-4D9F-B1D7-23361F1CD757 Q26796348-A411FB65-17AE-4FE1-B5C0-CEBB2483AECC Q26827212-7C8DAE89-4EFA-42A7-BC41-48072BC28DF7 Q26828992-79C8525A-005F-4C1E-8427-4D36563B70B7 Q26830362-D0C42110-EB7B-4EF4-9009-8000AFCB8E57 Q26851075-6D36BBAB-E682-475B-9D67-E5DD4E9D4D69 Q26862317-D853A747-5F00-4A9E-8E42-D8C75DC853EC Q26865436-12B6D2BA-FCFF-4D42-AD5C-3CB2520EEAC6 Q27003134-B2735E79-B9A2-404A-B36A-68DDB9ED1207 Q27006832-7090D789-CB3E-4C06-A428-4B258497ECA2 Q27015224-35899358-0F67-49FF-9DEA-47EE5B9B45F6 Q27022954-D0D65C4E-072D-4D51-8E8E-D0AD8DBC1BBB Q27025345-F13FFD35-CA05-4D66-9767-356878DD6AC0 Q27026516-F1719474-2793-468C-8911-8AD728B397D9 Q27027648-D7C179BF-00C3-44E1-9399-F7EBCF837A03 Q27027778-93D74EB7-F050-40F9-850E-342F31BCE36B Q27612411-0BBFA7D1-251B-4E9E-89D9-902E25AC8147

P2860

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q27851456

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@ast

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@en

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@nl

type

label

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@ast

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@en

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@nl

prefLabel

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@ast

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@en

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@nl

P1433

Q27851456-AE2508BC-C4E3-4A0C-AB13-01A37F455EC6

P1476

Q27851456-48B144DE-78B8-4FBC-B80D-2A185BE72F0B

P2093

Q27851456-35F39933-9AC5-4168-BF75-9D0930A65518

Q27851456-4D071817-78C9-41F1-8528-865D4B88ECA1

Q27851456-6A9E5AED-5DC8-424B-A064-10EBF14F6602

Q27851456-E0D9D16B-7BCB-4061-9E26-D355C0B29A40

Q27851456-F5D15016-8D7F-4734-BE2A-0DCF9277A540

P304

Q27851456-230AC49A-0066-476E-B262-BFC32C437CD1

P31

Q27851456-B3955E98-0EF2-46FA-8C32-AA61BDC8DD78

P3181

Q27851456-B53EE2F1-9175-4E8A-B76C-F0E9D86A6B2D

P356

Q27851456-772C79EB-68D0-4DB9-86D6-EAF0D41882ED

P407

Q27851456-6F2706FD-6B3E-4B66-8047-0D50E467BF2F

P433

Q27851456-BEA7C251-6737-4C67-915D-FDB323065E59

P478

Q27851456-ABF78204-1CA6-4AA9-919E-03965BF7EF32

P50

Q27851456-3F372AC7-4360-4159-B351-AA6243CEDDA6

Q27851456-4999BDDD-CE5D-4B0E-9A36-EC7602774C7A

Q27851456-5D5ECC0F-6B62-4C75-A16F-5CB10752845E

Q27851456-99372EC0-4E57-448A-8205-6E83543CA0A4

Q27851456-D6660F2A-BED0-4553-A0E0-EEC1EB58689E

Q27851456-EF0D67C9-57CB-4733-B657-80768F307D3D

P577

Q27851456-E0D1DD50-558D-4623-B9A7-9891FC535E45

P5875

Q27851456-33C241EC-295C-4F96-8705-75A2B625DFF7

P698

Q27851456-D3A3981E-8B14-492A-ABC5-33DA6454D3A7

P921

Q27851456-00DABCD5-2506-4FBA-A25C-79A48B892571

Q27851456-0E2DC82C-5E72-4423-A437-88F778088087

P3181

P356

JCO.2008.18.0786

P1433

Journal of Clinical Oncology

P1476

Wild-type BRAF is required for ...... metastatic colorectal cancer.

@en

P2093

Francesca Molinari

http://www.w3.org/2001/XMLSchema#string

Luca Mazzucchelli

http://www.w3.org/2001/XMLSchema#string

Milo Frattini

http://www.w3.org/2001/XMLSchema#string

Piercarlo Saletti

http://www.w3.org/2001/XMLSchema#string

Sara De Dosso

http://www.w3.org/2001/XMLSchema#string

P304

5705-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

118912

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2008.18.0786

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Federica Di Nicolantonio

Alberto Bardelli

Andrea Sartore-Bianchi

Salvatore Siena

P577

2008-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23465803

http://www.w3.org/2001/XMLSchema#string

P698

19001320

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer